[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637744":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":19,"responsibleParty":30,"collaborators":19,"id":32,"slug":19,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":19,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":19,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":19,"overallStatus":52,"whyStopped":19,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":19},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Arm","EXPERIMENTAL","QL1706 + Cisplatin\u002FPaclitaxel Neoadjuvant Therapy",[13],"Drug: QL1706 + Cisplatin\u002FPaclitaxel Neoadjuvant Therapy",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","QL1706 is a bifunctional PD-1\u002FCTLA-4 antibody combination consisting of iparomlimab and tuvonralimab.\n\nDrug: Cisplatin Cisplatin administered as part of neoadjuvant chemotherapy.\n\nDrug: Paclitaxel Paclitaxel administered as part of neoadjuvant chemotherapy.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Jianwei Zhou, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Zhigang Zhang, MD","CONTACT","86057189713631","zzg2011@zju.edu.cn",{"type":31,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100637744",false,"NCT07617818","QL1706 Combined With Cisplatin\u002FPaclitaxel as Neoadjuvant Therapy for Cervical Cancer","A Phase II, Single-Arm Study of QL1706 Combined With Cisplatin\u002FPaclitaxel as Neoadjuvant Therapy Prior to Conservative Surgery for FIGO 2018 Stage IB1-IB3 Cervical Cancer (CERVINA Study)","Inclusion Criteria:\n\n* Female patients aged 18-65 years.\n* Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* FIGO 2018 stage IB1, IB2, or IB3 cervical cancer.\n* Pelvic MRI completed before enrollment.\n* ECOG performance status of 0-2.\n* Adequate organ and bone marrow function.\n* No prior immunotherapy for malignant tumors.\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Presence of uncontrolled concomitant malignancies.\n* Active autoimmune disease or history of autoimmune disease with potential recurrence.\n* Interstitial lung disease or uncontrolled pneumonitis.\n* Active hepatitis B or hepatitis C infection.\n* Known HIV infection.\n* Receipt of live vaccines within 30 days before first dose.\n* Uncontrolled cardiovascular disease.\n* Known hypersensitivity to study drugs.\n* Any condition that, in the investigator's judgment, may interfere with study participation or interpretation of results.","FEMALE","18 Years","65 Years",{"count":42,"type":43},50,"ESTIMATED","INTERVENTIONAL",[46],"PHASE2","This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of QL1706 combined with cisplatin and paclitaxel as neoadjuvant therapy in patients with FIGO 2018 stage IB1-IB3 cervical cancer undergoing conservative surgery.\n\nThe primary endpoint is pathological complete response (pCR). Secondary endpoints include objective response rate (ORR), progression-free survival (PFS), overall survival (OS), 3-year pelvic recurrence rate, and safety profile.\n\nAdditionally, exploratory biomarker analyses will be conducted to investigate changes in immune status, genomic alterations, PD-L1 expression, tumor mutational burden, MSI-H\u002FdMMR status, and vaginal microbiota before and after treatment.",[49,50,51],"Cervical Cancer","Neoadjuvant Therapy","Immunotherapy","NOT_YET_RECRUITING","2026-05-26",{"date":55,"type":56},"2026-06-01","ACTUAL",{"date":58,"type":43},"2026-06-15",{"date":60,"type":43},"2029-12-15",{"name":5,"class":6}]